Search
for

    Learn

    5 / 12 results

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

      learn Bicalutamide

      a nonsteroidal anti-androgen, most commonly used orally for women

      learn Minoxidil

      An essential vasodilator with some anti-androgenic effects, has excellent safety record

      learn Ketoconazole

      antifungal with some anti-androgenic benefits, often used as a shampoo

      learn Spironolactone

      powerful topical and oral anti-androgen used mostly by women

    Research

    5 / 1000+ results

    Community Join

    5 / 368 results
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 4 months ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

      community Sweet Lord my DHT itch is finally gone

      in Chat  49 upvotes 1 year ago
      Hair loss itch stopped by adding RU58841 to treatment. Topical Finasteride and Pyrilutamide also mentioned as potential itch solutions.

      community Kintor Phase 2 Results released KX-826 (pyrilutamide)

      in Research/Science  451 upvotes 2 years ago
      Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

      community Anyone wanna try and interview the developers of RU?

      in Research/Science  83 upvotes 3 years ago
      The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.